GB-0895 / Generate Biomedicines - LARVOL DELTA

Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma (ERS 2025) - No abstract available

Late-breaking abstract • Asthma • Immunology • Respiratory Diseases

A long-acting high affinity anti-TSLP antibody (GB-0895) for severe asthma identified leveraging a proprietary machine learning platform (ERS 2024) - "The approved anti-TSLP antibody (tezepelumab) requires monthly administration; a longer duration treatment could improve adherence and outcomes. Conclusions GB-0895 has the potential for best-in-class dosing for patients with severe asthma. A phase 1 dose escalation trial in asthma patients is underway."

Machine learning • Asthma • Immunology • Inflammation • Respiratory Diseases